Vibliome
Bozeman
About Vibliome
Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $46.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2022)
- Website: vibliome.com
- Phone: (406) 595-3483
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vibliome-55688 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.